Efficacy of Beclomethasone Dipropionate HFA 200 ìg Once Daily in Chronic Obstructive Pulmonary Disease and Bronchial Asthma  

Oleh:

Tatsis, G. ; Kotsifas, K. ; Filaditaki, V. ; Makrantoni, G. ; Boulia, S.

Jenis: Article from Journal - ilmiah internasional
Dalam koleksi: The Journal of International Medical Research vol. 35 no. 03 (May 2007), page 361-373.
Topik: Beclomethasone Dipropionate HFA 200 ìg; chronic obstructive pulmonary disease; bronchial asthma

Ketersediaan

Perpustakaan FK Nomor Panggil: J11.K.2007.01 Non-tandon: 1 (dapat dipinjam: 0) Tandon: tidak ada

Lihat Detail Induk

Isi artikel

The efficacy and safety of once-daily beclomethasone dipropionate (BDP; 200 micrograms), in combination with the propellant hydrofluoroalkane-134a (HFA) was compared with that of budesonide turbuhaler (BUD-TH) 400 micrograms twice daily and fluticasone propionate inhaler (FP-IH) 250 micrograms twice daily in 40 patients with bronchial asthma or chronic obstructive pulmonary disease. All patients had used inhaled corticosteroids for at least 1 month. On randomization, 20 patients were switched to HFA–BDP and 20 patients remained on their existing BUD-TH or FP-IH treatment. After 8 weeks, HFA–BDP demonstrated a greater improvement in spirometric values, respiratory symptoms and beta2-agonist use. No significant local adverse effects were observed. Blood cortisol levels remained in the normal range in both groups. We conclude that HFA–BDP (200 micrograms once-daily) offered more benefit in terms of clinical and spirometry indices than BUD-TH (400 micrograms twice daily) or FP-IH (250 micrograms twice daily) in patients with moderate asthma and chronic obstructive pulmonary disease.

Opini Anda

Klik untuk menuliskan opini Anda tentang koleksi ini!

Kembali